Trial · NCT01313624
Adverse events304
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 304
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cough | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 69 | 134 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 57 | 132 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 35 | 96 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 50 | 122 | |
| other | Sputum Increased | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 62 | 134 | |
| other | Sputum Increased | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 48 | 132 | |
| other | Sputum Increased | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 29 | 96 | |
| other | Sputum Increased | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 36 | 122 | |
| other | Sputum discoloured | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 42 | 134 | |
| other | Sputum discoloured | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 33 | 132 | |
| other | Sputum discoloured | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 24 | 96 | |
| other | Sputum discoloured | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 26 | 122 | |
| other | Haemoptysis | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 8 | 134 | |
| other | Haemoptysis | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 12 | 132 | |
| other | Haemoptysis | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 5 | 96 | |
| other | Haemoptysis | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 9 | 122 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Double-Blind) | 73 | 134 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Double-Blind) | 47 | 132 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | AZLI-AZLI (Open-Label) | 31 | 96 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo-AZLI (Open-Label) | 47 | 122 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01313624/events